A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia.

Published in: Hematology (Amsterdam, Netherlands) (2024)

An immune-ERG-based risk model was developed to effectively predict prognostic outcomes for AML patients. There is potential for immune therapy in AML targeting the five hub genes.

Keyphrases

acute myeloid leukemia
end stage renal disease
chronic kidney disease
ejection fraction
prognostic factors
allogeneic hematopoietic stem cell transplantation
gene expression
metabolic syndrome
type diabetes
adipose tissue
cancer therapy
mesenchymal stem cells
drug delivery
dna methylation
patient reported